Dec 2 2014
AYOXXA Biosystems GmbH, an international biotechnology company, announces the closing of a third round of Series B financing, bringing the total amount raised to 11.3 Mio. EUR in 2014. An additional 2.3 Mio. EUR were now invested by BioMedPartners AG, Basel and Grazia Equity GmbH, based in Stuttgart, Germany. Both leading European venture capital firms joined the group of established AYOXXA investors, who successfully closed second round in June 2014.
"These funds will allow us to continue our production ramp-up efforts as well as to speed-up our global commercial activities," said Dr. Andreas Schmidt CEO and Co-founder of AYOXXA Biosystems GmbH.
"We are excited to work with AYOXXA to drive the commercialization of this state-of-the-art multiplex-protein analysis technology," Dr. Karsten Fischer, BioMedPartners AG commented. "Together with the unique small volume format, this method is enabling research, development and even potential diagnostic questions, so far inaccessible."
Alec Rauschenbusch, Managing Partner of Grazia Equity GmbH: "With its highly innovative multiplexing system, AYOXXA is setting new standards for applications and analysis of high-value biological samples in the area of medical research and pharmacological screening."
Additionally, the company announces that Andreas Richter will take over the function as CFO in AYOXXA's Executive Management Team, effective January 1st 2015. "I am pleased to become part of AYOXXA's business journey. The Series B financing round closed remarkably successful. We will leverage the financial assets to transform from a research-focused into a market-driven company. It is our goal to be partner of choice for life science researchers looking for a robust and flexible protein testing solution," Richter stated.
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses